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Tumor necrosis factor alpha (TNF-α) is an important pro-inflammatory cytokine associated with a variety of ocular
diseases. The currently available TNF-α inhibitors are etanercept, infliximab, adalimumab, golimumab, and certolizumab.
Experimental and clinical studies on the intravitreal use of these agents have been reported with etanercept, infliximab,
and adalimumab: etanercept has shown limited efficacy in scarce reports; infliximab has been associated with local
safety concerns but appears to benefit certain cases; adalimumab has shown no efficacy in cases of age-related macular
degeneration (AMD) or diabetic macular edema (DME), but the combination with bevacizumab may be effective in
refractory cases of macular diseases. Further preclinical and clinical studies are warranted in order to be able to obtain
a more robust conclusion on the use of intravitreal TNF-α inhibitors.
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Introduction
Inflammation has been implicated as one of the pivotal
mediators of retinal injury in the pathogenesis of most
sight-threatening ocular diseases including uveitis, diabetic
retinopathy and diabetic macular edema (DME), and atro-
phic and neovascular age-related macular degeneration
(AMD) [1,2]. Thus, a variety of anti-inflammatory and
immunomodulatory agents have been tested as potential
single or combination therapies in the management of
intraocular inflammation, hyperpermeability, and neo-
vascularization. Traditionally, corticosteroids have been
the standard approach to this inflammatory pathway
inhibition. However, their systemic and ocular safety
profiles limit their use [3].
Tumor necrosis factor alpha (TNF-α) is an important
pro-inflammatory cytokine with pleiotropic functions
synthesized mainly by T lymphocytes and macrophages
and to a lesser extent by neutrophils and mast cells
[4]. It plays a major role in the regulation of immune
cells, inhibition of tumorigenesis, and inhibition of viral
replication [5-8].* Correspondence: rosadolzmarco@gmail.com
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reproduction in any medium, provided the origThe currently available TNF-α inhibitors are etanercept,
infliximab, adalimumab, golimumab, and certolizumab.
Etanercept (Enbrel; Pfizer Inc; New York, NY, USA) is a
TNF receptor-IgG fusion protein that mimics the inhibi-
tory effects of naturally occurring soluble TNF receptors
that is injected subcutaneously. Infliximab (Remicade;
Schering-Plough, Rathdrum, Ireland) is a mouse-human
chimeric antibody that neutralizes the biological activity
of TNF-α by high-affinity binding to the soluble and
transmembrane forms of TNF-α, therefore preventing
the effective binding of TNF-α with its receptors. It is
administered intravenously. Adalimumab (Humira; AbbVie
Inc., North Chicago, IL, USA) is a fully human monoclonal
antibody that also binds selectively all forms of TNF-α.
It is also injected subcutaneously. Golimumab (Simponi;
Centocor, Horsham, PA, USA, and Schering-Plough,
Rathdrum, Ireland) is a fully human monoclonal antibody
against TNF-α that is administered via a subcutaneous
injection. Certolizumab (Cimzia; UCB Pharma, Brussels,
Belgium) is a monoclonal antibody that combines the Fab
fragment of the TNF antibody with polyethylene glycol
that is delivered subcutaneously. Table 1 summarizes the
main features of these molecules.
Reported risks of the systemic administration (intraven-
ous or subcutaneous) of TNF-α inhibitors include fatal
blood disorders, secondary infections, and reactivation ofThis is an Open Access article distributed under the terms of the Creative
mmons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
inal work is properly credited.
Table 1 Summary of the main features of the currently available tumor necrosis factor alpha inhibitors
Generic name (brand name) Molecular weight (kDa) Mechanism of action Route of administration Half-life (days)
Etanercept (Enbrel) 150 TNF soluble decoy receptor Subcutaneous injection 4 to 6
Infliximab (Remicade) 149 Anti-TNF monoclonal antibody Intravenous infusion 8 to 10
Adalimumab (Humira) 148 Anti-TNF monoclonal antibody Subcutaneous injection 14
Golimumab (Simponi) 150 to 151 Anti-TNF monoclonal antibody Subcutaneous infusion 14
Certolizumab (Cimzia) 91 Pegylated anti-TNF monoclonal antibody Subcutaneous injection 14
kDa, kilodalton; TNF, tumor necrosis factor.
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demyelinating central nervous system disorders among
others. These potentially severe adverse events led to
the investigation by ophthalmologists of alternative
administration routes minimizing these risks but pre-
serving the efficacy of the drugs. The possibility of
performing intravitreal injection of TNF-α inhibitors
could fulfill both needs [9]. However, no well-designated
trials have been conducted to date [9-11], and the use of
the intravitreal route of administration of TNF-α inhibi-
tors has not been generalized.
The purposes of the present review are to analyze the
current published evidence with regard to intravitreal
injection of TNF-α inhibitors and to summarize the
outcomes with this novel therapeutic approach.
Methods
A systematic review of all the peer-reviewed articles
indexed in PubMed was performed. A comprehensive
search of the literature was conducted using the online
biomedical search engine PubMed. Search terms included
the following: intravitreal, etanercept, infliximab, adali-
mumab, golimumab, certolizumab, tumor necrosis factor
inhibitors. No publication date limit was applied, thus
including all the available reports. Preclinical experimental
models, clinical case reports, pilot studies, and case
series were reviewed independently for the intravitreal
use of etanercept, infliximab, and adalimumab. Relevant
articles cited in papers retrieved from PubMed were
also reviewed. No preclinical or clinical experience with
intraocular administration of golimumab or certolizumab
was found.
Intravitreal experience with etanercept
Experimental animal models showed that intravitreal in-
jections of etanercept up to 2.5 mg may be well tolerated
without significant toxic effects on the retina [12,13].
Clinical experience has been limited to a small pilot
study that included seven patients with refractory DME
[14]. Following two intravitreal injections of 2.5 mg (0 and
1 mL) of etanercept with a 2-week interval, no adverse
event was registered, obtaining no significant improve-
ment in 3 months after initiation of this treatment [14].
There is no scientific background that may reinforce theuse of intravitreal injections of etanercept for the manage-
ment of ocular diseases.
Intravitreal experience with infliximab
Experimental animal models showed that intravitreal
injections of infliximab were tolerated up to 2.0 mg.
However, doses higher than 3.3 mg may be potentially
toxic to the retina [15-20]. Also, Regatieri et al. showed
in a laser-induced choroidal neovascularization model
that intravitreal infliximab when injected at doses of 10
to 40 μg has an anti-angiogenic effect, whereas higher
doses (320 μg) showed pro-angiogenic effects [21]. More
recently, Yuksel et al. evidenced in a rabbit model of
experimental endotoxin-induced uveitis that intravenous
administration of infliximab was more effective than the
intravitreal route in an acute period [22].
Beer et al. suggested that infliximab may be suitable for
compounding and could be a cost-effective intravitreal
medication for use in clinical practice [23]. A summary of
the clinical experience reported is provided in Table 2.
Theodossiadis and colleagues treated three patients
with exudative AMD unresponsive to ranibizumab with
two injections of 2 mg of infliximab given 2 months
apart [24]. They reported visual improvement in all three
cases (20/200 to 20/40; 20/200 to 20/70; and 20/100 to
20/30) with no safety concerns. In contrast, Giganti et al.
reported that intravitreal infliximab at a dose of 0.5 mg in
two eyes of DME and in two cases of neovascular AMD
was associated with anatomic, electroretinographic, and
microperimetric worsening, and three of these cases
developed intraocular inflammation [25]. Arias et al.
conducted a prospective interventional trial of four eyes
with exudative AMD refractory to anti-vascular endo-
thelial growth factor (VEGF) agents. They reported that
intravitreal infliximab at a dose of 2 mg did not provide
any visual or anatomic benefit. Furthermore, half of their
patients developed a severe intraocular inflammatory reac-
tion [26]. The Pan-American Collaborative Retina Study
Group has published the largest series on the use of intra-
vitreal infliximab in both DME and exudative AMD. In
their series, eyes with refractory DME received a single
intravitreal injection of infliximab 1.0 mg/0.05 mL (15 eyes)
or 2.0 mg/0.10 mL (19 eyes). No significant anatomical or
functional benefit was evidenced. In addition, 42% of eyes
Table 2 Summary of publications regarding the use of intravitreal infliximab
Publications Indication Dosing Number of cases Main results
Theodossiadis
et al. [17]
Neovascular AMD 2.0 mg/0.05 mL 3 BCVA improved from 20/200 to 20/40 after two monthly injections in
case 1, from 20/200 to 20/70 after two bimonthly injections in case 2,
and from 20/100 to 20/30 after two injections with a 3-month interval.
Giganti et al. [25] Neovascular AMD 0.5 mg/0.05 mL 2 At week 12, BCVA had declined in three patients, and
electroretinography and microperimetry had a decrease in all cases.
DME 0.5 mg/0.05 mL 2
Arias et al. [26] Neovascular AMD 2.0 mg/0.05 mL 4 At 3 months after a single injection, the BCVA change was −18, +3, +4,
and −4 letters.
Two cases developed severe intraocular inflammation.
Wu et al. [27] DME 1.0 mg/0.05 mL 15 BCVA changed from 1.49 ± 0.58 to 1.38 ± 0.56 logMAR at 3 months
in the 1 mg group.
2.0 mg/0.10 mL 19 BCVA changed from 0.76 ± 0.5 to 1.03 ± 0.7 logMAR at 3 months in
the 2 mg group,
and 42% of cases developed severe intraocular inflammation.
Wu et al. [28] Neovascular AMD 1.0 mg/0.05 mL 8 BCVA changed from 1.04 ± 0.2 to 1.06 ± 0.5 logMAR at 3 months in
the 1 mg group.
2.0 mg/0.10 mL 8 BCVA changed from 0.94 ± 0.5 at baseline to 0.85 ± 0.4 logMAR in
the 2 mg infliximab group.
37.5% of eyes developed severe intraocular inflammation.
Farvardin et al. [29,30] NIPU 1.5 mg/0.15 mL 7 BCVA changed from 1.37 ± 0.4 to 1.38 ± 0.4 logMAR at 6 months.
Vitreous haziness changed from 2.7 to 2.6 at 6 months.
Markomichelakis
et al. [31]
Behçet 1.0 mg/0.05 mL 15 BCVA changed from 0.74 to 0.3 logMAR at 30 days.
Intraocular inflammation decreased through day 30.
Wu et al. [32] PCME 1.0 mg/0.10 mL 7 BCVA changed from 1.14 ± 0.6 to 0.51 ± 0.35 logMAR.
Mild intraocular inflammation was observed in one case.
AMD, age-related macular degeneration; DME, diabetic macular edema; NIPU, noninfectious posterior uveitis; PCME, pseudoaphakic cystoid macular edema; BCVA,
best-corrected visual acuity; logMAR, logarithm of the minimal angle of resolution.
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of these eyes (37.5%) required pars plana vitrectomy
[27]. Similar results were found in 26 eyes with partially
responsive neovascular AMD to intravitreal injections
of VEGF inhibitors. No functional gains were seen, and
in addition, 37.5% of patients developed a severe uveitis
that resolved with intensive topical steroid therapy [28].
Farvardin et al. reported positive both short- and long-
term (6 months) outcomes after intravitreal infliximab
1.5 mg/0.15 mL in ten eyes of seven patients with chronic
persistent noninfectious uveitis without any ocular adverse
event, showing a visual mean visual improvement from
1.37 logMAR to 0.67 logMAR 1 month after the injection,
which was not sustained by month 6 due to recurrence of
macular edema and vitreous haze [29,30].
Markomichelakis et al. reported that a single intravitreal
injection of infliximab 1.0 mg/0.05 mL controlled intraoc-
ular inflammation in 15 cases with relapsing posterior
uveitis associated with Behçet's disease [31].
Wu et al. found that a single intravitreal injection of
infliximab 1.0 mg/0.10 mL achieved excellent outcomes
after 6 months, without any intraocular inflammation, in
seven cases of refractory pseudophakic cystoid macular
edema [32].Intravitreal experience with adalimumab
Experimental animal models have shown that intravitreal
injections of adalimumab were tolerated up to 5.0 mg
without electroretinographic or histological alterations
[33]. However, doses of 10.0 mg have been associated
with early retinal toxicity and a significant decrease in
the photopic wave in the electroretinographic response
[34,35].
The Pan-American Collaborative Retina Study Group
published their clinical experience with intravitreal injec-
tions of adalimumab for patients with refractory DME
and partially responsive neovascular AMD to VEGF in-
hibitors. Intravitreal injections of adalimumab 2.0 mg/
0.08 mL did not provide any anatomical or functional
benefit in five cases of DME nonresponsive to conven-
tional therapies and four cases of neovascular AMD. No
ocular side effects were reported by the authors following
intravitreal injections of adalimumab [26,27].
The possible role of intravitreal adalimumab in com-
bination with anti-angiogenic agents (bevacizumab) has
also been analyzed by these authors. In their case series
of seven eyes of five patients with macular edema of
various etiologies including partially responsive neovas-
cular AMD, a clinically relevant response was achieved
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2 mg/0.08 mL and bevacizumab 1.25 mg/0.05 mL [36].
Conclusions
Overall, the literature review of all published manuscripts
regarding the use of intravitreal TNF-α inhibitors reveals
the following conclusions: 1) intravitreal injections of
etanercept may not be useful in the management of
ocular diseases, 2) intravitreal injections of infliximab may
potentially be related to severe intraocular inflammation,
3) intravitreal injections of infliximab do not appear to
benefit cases of refractory DME or partially responsive
neovascular AMD, 4) intravitreal injections of infliximab
may benefit cases of persistent noninfectious posterior
uveitis and refractory pseudophakic cystoid macular edema,
5) intravitreal injections of adalimumab do not appear to
benefit cases of DME or neovascular AMD, 6) intravitreal
combination of adalimumab and bevacizumab may be ef-
fective in the management of cases with partially responsive
neovascular AMD and macular edema of various etiologies,
and 7) no preclinical or clinical experience with intravitreal
golimumab or certolizumab has yet been published.
It is important to emphasize that all the reviewed
reports include small samples, variable endpoints and
follow-up periods, and heterogeneity in the doses
administered, the selection criteria, and the patient
population [9-11]. The off-label intravitreal use of any
drug should be cautiously considered given the potentially
severe adverse events that this procedure may induce.
Further preclinical and clinical studies are warranted in
order to be able to obtain a more robust conclusion on
the use of intravitreal TNF-α inhibitors.
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